Výsledky vyhledávání - "Daniel Handerson Galindo Soares"

Akademický článek

Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma

Autor: Camila Bezerra Melo Figueirêdo, Joelma Rodrigues de Souza, Daniel Handerson Galindo Soares, Caio Cesar de Andrade Rodrigues Silva, Virginia Maria Barros de Lorena

Publikováno v: Brazilian Journal of Pharmaceutical Sciences, Vol 50, Iss 3, Pp 445-455 (2014)

Non-Hodgkin's lymphoma (NHL) consists of a group of neoplasias involving mainly B cells and represents 90% of all lymphomas. The current available therapy is based on chemotherapy associated with the monoclonal antibody rituximab (Mab Thera(r)), whic

Externí odkaz: https://doaj.org/article/5b034ec7156f4d16a08582b6fa52bfe4

Zobrazit plný text záznamu

Clinical and economic aspects of the use of rituximab in non-Hodgkin's lymphoma

Autor: Daniel Handerson Galindo Soares, Virgínia Maria Barros de Lorena, Caio César de Andrade Rodrigues Silva, Camila Bezerra Melo Figueirêdo, Joelma Rodrigues de Souza

Publikováno v: Brazilian Journal of Pharmaceutical Sciences; Vol. 50 No. 3 (2014); 445-455
Brazilian Journal of Pharmaceutical Sciences; Vol. 50 Núm. 3 (2014); 445-455
Brazilian Journal of Pharmaceutical Sciences; v. 50 n. 3 (2014); 445-455
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP
Brazilian Journal of Pharmaceutical Sciences, Volume: 50, Issue: 3, Pages: 445-455, Published: SEP 2014
Brazilian Journal of Pharmaceutical Sciences, Vol 50, Iss 3, Pp 445-455 (2014)

O Linfoma não-Hodgkin (LNH) consiste em um grupo de neoplasias envolvendo, principalmente, as células B e representa 90% de todos os linfomas. A terapia atual disponível é baseada em quimioterapia associada ao anticorpo monoclonal rituximabe (Mab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd507aad2d10ac7e1e143e1f7be8a37
https://doi.org/10.1590/s1984-82502014000300002

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání